1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

'Positive' Signs Abound For Perrigo, But 'Uncertainty' From Pandemic Complicates Outlook

 
• By Malcolm Spicer

"With all the positive things, I'd normally be raising guidance right now," says CEO Murray Kessler as Perrigo reports first-quarter results. But manufacturing operations aren't normal, and neither is the consumer health product marketplace.

"Uncertainty Ahead” sign on a background of blue sky with clouds

Perrigo Co. PLC would have an outlook that couldn't be better if it wasn't for the uncertainty the COVID-19 pandemic imposes on manufacturing and the marketplace.

The OTC private label and store brand giant, with presence also in the infant formula, branded nutritional product and generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 
• By Malcolm Spicer

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By Tom Gallen

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’

 
• By Malcolm Spicer

PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.

Reducing ‘Complexity Across The Organization’ Tops Kenvue Interim CEO’s Priorities

 
• By Malcolm Spicer

Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”

More from Business

Futura Launches Eroxon Strategic Review

 
• By Tom Gallen

Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.

Reducing ‘Complexity Across The Organization’ Tops Kenvue Interim CEO’s Priorities

 
• By Malcolm Spicer

Three weeks into his appointment as interim CEO, Kirk Perry sets priorities including “reduce organizational complexity,” “reinforce a consumer-centric mindset” and “refocus on household penetration.”

Softness In US And China Holds Back Bayer Consumer Health

 
• By Tom Gallen

Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.